1 Top-Down vs Step-Up Trial Endoscopic Substudy: Mucosal Healing Patients, % 88 71 47 30 P<0.001 0 20 40 60 80 100 Reduction of Ulcers Disappearance of.

Slides:

Advertisements

Similar presentations

Crohns Disease: Managing and Monitoring Mucosal Healing in the Small Bowel

Advertisements

Monotherapy using 6-MP or azathioprine for Crohn’s disease is dead: out with the old and in with the new Stephen B. Hanauer, MD Professor of Medicine Clinical.

Miguel Regueiro, M.D. Professor of Medicine

Immunomodulators and Biologics Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida.

Thomas Ullman, M.D. Chief Medical Officer

A patient with severe Crohn's disease, an ileal stricture and proximal dilation on CTE should have medical therapy first Uma Mahadevan MD Professor of.

Miguel Regueiro, M.D. Professor of Medicine

Thiopurines still have a role in the management of pediatric IBD Athos Bousvaros MD, MPH Associate Director, IBD program Boston Children’s Hospital.

Quando sospendere la terapia biologica ? Claudio Bilardi Modulo di Gastroenterologia Ospedale Villa Scassi Genova, 26 Novembre 2011, Hotel Sheraton.

Positioning Our Recent & Future Therapy in Crohn’s disease

End points in IBD treatment Mucosal healing Vs Symptom relief Jose Francis Lakeshore Hospital Kochi.

Immunomodulators and Biologics

6-MP and AZA Applications and Approaches

Immunosuppressive Medications and IBD: Now and What’s Next

Monotherapy using 6-MP or azathioprine for IBD is not dead yet: long live the tried and true Jean-Frederic Colombel Icahn School of Medicine at Mount Sinai.

Q UALITY R EPORTING F OR C OLONOSCOPY I N IBD Gil Y. Melmed, MD, MS Cedars-Sinai Medical Center CCFA Advances in IBD Orlando, FL December 2014.

Prevention of Postoperative Crohn’s disease

Asymptomatic UC patients on an immunomodulator with persistent moderate mucosal inflammation should either add a biologic or switch to a biologic William.

Biologics: Indications and Approaches Russell D. Cohen, MD, AGAF, FACG Professor of Medicine, Pritzker School of Medicine Director IBD Center Co-Director.

Therapeutic algorithms for Crohn’s disease: Where are we in 2012?

Jean-Frédéric Colombel

William J. Sandborn, MD Chief, Division of Gastroenterology

A personalized approach to choosing therapies in IBD: Can we do this smarter? Stephen B. Hanauer, MD.

Controversies and challenges in the clinical care of patients with IBD: You can’t always get what you want! Stephen B. Hanauer, MD University of Chicago.

Evidence-Based Medicine Changing Practice Dr Feagan’s Top 10 Clinical Trials c/o Dr Brian Feagan Presented and updated by Barrett Levesque MD, Director,

“Antibiotics and corticosteroids: Indications and approaches”

Crohn’s disease the new challenge Dr.Nahla A Azzam (MRCP) GI/ Medicine Consultant KKUH.

The only end-points of therapy that matter are mucosal healing, normal blood work, and negative radiologic studies. Robert N. Baldassano, MD Colman Family.

Background  Certolizumab pegol is a pegylated humanised Fab’ fragment of a monoclonal antibody with high specificity for human TNF α  Phase II studies.

You Can Never Stop a Biologic

Early Administration of Azathioprine Versus Conventional Management of Crohn’s Disease : A Randomized Controlled Trial F1. Ja Won Koo JACQUES COSNES, ANNE.

Xavier Roblin, MD, PhD 1, M. Rinaudo, MD 2, E. Del Tedesco, MD 1, J.M. Phelip, MD, PhD 1, C. Genin, MD, PhD 2, L. Peyrin-Biroulet, MD, PhD 3 and S. Paul,

Am J Gastroenterol 2010; 105:1820–1829 F1 박재현. Background Background A novel mouse line with defects in both transforming growth factor- β type II receptor.

MIGUEL REGUEIRO, WOLFGANG SCHRAUT, LEONARD BAIDOO, KEVIN E. KIP, ANTONIA R. SEPULVEDA, MARILYN PESCI, JANET HARRISON, SCOTT E. PLEVY GASTROENTEROLOGY 2009;136:441–450.

Learning Objectives Describe the relationship between the JAK-STAT signaling pathway and pathogenesis of inflammatory bowel disease. Summarize the latest.

Cumulative Probability of Developing Colon Cancer in UC Patients

Rahul A. Nathwani, MD, FACG

Volume 138, Issue 2, Pages (February 2010)

Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab William J. Sandborn, Maria T. Abreu, Geert.

Raymond Cross, MD, MS, AGAF Associate Professor of Medicine

Volume 154, Issue 1, Pages e6 (January 2018)

Illustrations in Ulcerative Colitis

Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean–Frédéric Colombel, William.

Volume 130, Issue 2, Pages (February 2006)

Optimizing Outcomes in Crohn Disease

Volume 147, Issue 3, Pages e3 (September 2014)

Baseline scores and corresponding changes to week 96 of the RAPID-axSpA trial for all CZP-treated patients included in the imaging substudy for: (A) SPARCC.

Adalimumab Induces Deep Remission in Patients With Crohn's Disease

William J. Sandborn, Stefan Schreiber, Brian G

Volume 145, Issue 5, Pages e5 (November 2013)

Volume 132, Issue 1, Pages (January 2007)

Clinical and patient-reported outcomes for patients randomised to CZP 200 mg Q2W and CZP 400 mg Q4W to week 96. Clinical and patient-reported outcomes.

Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.

Volume 121, Issue 5, Pages (November 2001)

Efficacy outcomes in patients aged ≥65 years versus younger patients: ACR outcomes at (A) week 12 and (B) week 24. Efficacy outcomes in patients aged ≥65.

Volume 126, Issue 2, Pages (February 2004)

Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study William J. Sandborn, Stefan Schreiber,

Phase III randomized controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: 1-year.

Volume 116, Issue 5, Pages (May 1999)

Volume 142, Issue 5, Pages e2 (May 2012)

Volume 117, Issue 3, Pages (September 1999)

Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial Paul Rutgeerts, MD,

Volume 142, Issue 2, Pages e3 (February 2012)

Endoscopic Assessment and Treating to Target Increase the Likelihood of Mucosal Healing in Patients With Crohn’s Disease Guillaume Bouguen, Barrett G.

Slides compiled by Dr. Najma Ahmed

Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months Gary R. Lichtenstein, Ole Ø. Thomsen,

Volume 157, Issue 4, Pages e6 (October 2019)

Patient Heterogeneity in CD

Study design. Study design. Patients who completed the 8-week induction study and achieved clinical response-100 (decrease in Crohn's disease activity.

(A) Percentage of patients achieving remission or response at week 12 or 24 after initiating ova therapy. (A) Percentage of patients achieving remission.

Presentation transcript:

1 Top-Down vs Step-Up Trial Endoscopic Substudy: Mucosal Healing Patients, % P< Reduction of Ulcers Disappearance of Ulcers Early combined immunosuppression (top-down; n=66) Conventional management (step-up; n=67) D’Haens G, et al. Lancet. 2008;371:

2 Mucosal Healing Predicts Sustained Clinical Remission in Early CD Simple endoscopic score 0 Simple endoscopic score Patients, % 0 RemissionRemission, No Steroids Remission, No Steroids, No Flare Remission, No Steroids, No Flare, No Anti-TNF abb b a P <0.05; b P <0.01 (Fischer’s exact) Baert FJ, et al. Presented at Digestive Disease Week. May 17-22, 2008; San Diego, CA; #W1133. Patients in remission at years 3 and 4

3 SONIC Mucosal Healing at Week Patients, % P<0.001 P=0.023P= /10928/9347/107 AZA + placebo IFX + placebo IFX+ AZA Sandborn WJ, et al. Presented at American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course. October 3-8, 2008; Orlando, FL.

4 The MUSIC Trial Endoscopic Mucosal Lesion Healing With Certolizumab Pegol a CDEIS score<7; b CDAI score ≤150 points; c ≥4-point change in CDEIS score. CDAI, Crohn’s disease activity index; CDEIS, Crohn’s disease endoscopic index of severity; MUSIC, Endoscopic Mucosal Improvement in Patients with Active Crohn's Disease Treated With Certolizumab Pegol. Colombel J. Am J Gastroenterol. 2008;103:S-132(1107) Remission and Response Rates, % Response, CDEIS c Remission, CDEIS a Remission, CDAI b Observed improvement in endoscopic and histologic lesions